DIGIFab® Manufacturing Process1,2
Quality Assurance Through a Proven, Time-Intensive,
and Complex Process
Immunogens consisting of an analogue of digoxin are produced in a laboratory and used to immunise sheep
The immune system recognises these antigens as foreign and produces antibodies
The antibodies are then collected, separated, purified, and formulated into DIGIFab®
References
- Data on file. BTG International Ltd.
- Maes K, Depudyt P, Vermassen J, et al. Foxglove poisoning: diagnostic and therapeutic differences with medicinal digitalis glycosides overdose. Acta Clinica Belgica. 2022;77(1):101-107